Listen to this article

Source: EndoQuest

EndoQuest Robotics Inc. and Omnivision have partnered to integrate Omnivision’s CameraCubeChip into EndoQuest’s surgical robotic system.

Santa Clara, Calif.-based Omnivision develops semiconductor systems, including advanced digital imaging and touch display technology.

Houston-based EndoQuest designed its system to address unmet needs in gastrointestinal and other endoluminal surgeries. The company said its proprietary technology navigates within the body’s lumina spaces such as the intestine. This provides the precision and flexibility for minimally invasive interventions, which can improve patient outcomes, it said.

EndoQuest added that its platform allows therapeutic endoscopists and surgeons to operate through a trans-oral or trans-anal approach. Last month, the company raised $42 million. Last week, the U.S. Food and Drug Administration’s Safer Technologies Program (STeP) accepted the surgical robotic system.

Omnivision to enable clearer surgical visualization

Omnivision designed the CameraCubeChip visualization system with its PureCel Plus-S pixel technology.

PureCel Plus-S enables “high full-well capacity, zero blooming and lower power consumption with crisp, clear, life-like images,” said Tehzeeb Gunja, director of medical marketing at Omnivision. He added that the compact, medical-grade offering could take patient care and surgical visualization “to the next level.”

“We are excited to be able to incorporate Omnivision’s market-leading sensor technology into the visualization component of our first-of-its-kind platform,” said Kurt Azarbarzin, CEO of EndoQuest Robotics, in a release. “We recognize that advanced imaging is essential to enhancing physician capabilities, especially inside the lumen of the gastrointestinal (GI) tract. Omnivision’s newest technology is ideal for our flexible robotic system.”

EndoQuest expects STeP to accelerate access

STeP provides a streamlined development and market review process for eligible medical devices with the goal of accelerating patient access without compromising safety and efficacy. The FDA launched STeP in 2021, modeling the program on its breakthrough devices designation program.

STeP covers devices that could improve the safety of treatments or diagnostics. They must be designed to treat underlying diseases or conditions considered less serious than those treated or diagnosed by devices eligible for breakthrough designation.

“We believe that our unique robotic platform will enhance physician control, precision, and efficiency, enabling safer and more effective minimally invasive treatments,” stated Azarbarzin. “We look forward to working with the FDA to bring the Flexible Robotic System to market and provide physicians and patients a new, scar-free approach for a wide variety of medical conditions and procedures.”

Editor’s note: This article was syndicated from MassDevice, a sibling site to The Robot Report.